

CITATION REPORT

List of articles citing

Molecular markers for bladder cancer screening, early diagnosis, and surveillance: the WHO/ICUD consensus

DOI: 10.1159/000369357

Urologia Internationalis, 2015, 94, 1-24.

Source: <https://exaly.com/paper-pdf/61973132/citation-report.pdf>

Version: 2024-04-23

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
132	The fascinating story of urine examination: From uroscopy to the era of microscopy and beyond. 2015 , 43, 1020-36		13
131	Use of Lectin Affinity Chromatography to Enrich Candidate Biomarkers from the Urine of Patients with Bladder Cancer. 2015 , 3, 266-282		5
130	Molecular markers for bladder cancer screening, early diagnosis, and surveillance: the WHO/ICUD consensus. <i>Urologia Internationalis</i> , 2015 , 94, 1-24	1.9	114
129	Biomarkers for bladder cancer: The search continues!. <i>Investigative and Clinical Urology</i> , 2016 , 57, 73-4	1.9	
128	Follow-up in non-muscle-invasive bladder cancer-International Bladder Cancer Network recommendations. 2016 , 34, 460-8		37
127	A Systematic Review of the Diagnostic and Prognostic Value of Urinary Protein Biomarkers in Urothelial Bladder Cancer. 2016 , 2, 301-317		63
126	The Clinical Use of the Neutrophil to Lymphocyte Ratio (NLR) in Urothelial Cancer: A Systematic Review. 2016 , 14, 473-484		62
125	Microhematuria assessment an IBCN consensus-Based upon a critical review of current guidelines. 2016 , 34, 437-51		18
124	Replacing cystoscopy by urine markers in the follow-up of patients with low-risk non-muscle-invasive bladder cancer?-An International Bladder Cancer Network project. 2016 , 34, 452-9		17
123	Promoter hypermethylation of HS3ST2, SEPTIN9 and SLIT2 combined with FGFR3 mutations as a sensitive/specific urinary assay for diagnosis and surveillance in patients with low or high-risk non-muscle-invasive bladder cancer. <i>BMC Cancer</i> , 2016 , 16, 704	4.8	46
122	Bladder cancer. 2016 , 388, 2796-2810		669
121	Novel fusion transcripts in bladder cancer identified by RNA-seq. 2016 , 374, 224-8		21
120	Current Status of Urinary Biomarkers for Detection and Surveillance of Bladder Cancer. 2016 , 43, 47-62		58
119	Urinary Cell-Free DNA Quantification as Non-Invasive Biomarker in Patients with Bladder Cancer. <i>Urologia Internationalis</i> , 2016 , 96, 25-31	1.9	26
118	Urinary biomarkers for the diagnosis of urothelial bladder cancer. 2017 , 3, 221		0
117	A platform for selective immuno-capture of cancer cells from urine. 2017 , 96, 373-380		39
116	The value of the UroVysion FISH assay in the risk-stratification of patients with "atypical urothelial cells" in urinary cytology specimens. 2017 , 45, 481-500		23

115	Evaluation of the diagnostic accuracy of UBC Rapid in bladder cancer: a Swedish multicentre study. 2017 , 51, 293-300	13
114	An integrated double-filtration microfluidic device for isolation, enrichment and quantification of urinary extracellular vesicles for detection of bladder cancer. 2017 , 7, 46224	136
113	Hyaluronic acid family in bladder cancer: potential prognostic biomarkers and therapeutic targets. 2017 , 117, 1507-1517	33
112	Bladder cancer: Present and future. 2017 , 149, 449-455	63
111	Noninvasive detection of bladder cancer using mid-infrared spectra classification. 2017 , 89, 333-342	10
110	Prognostic and Predictive Markers, and Stratifications Tables, for the Detection and Treatment of Renal Cell Carcinoma. 2017 , 1-17	1
109	Bladder cancer: Present and future. 2017 , 149, 449-455	7
108	Clinical Utility of Cxbladder for the Diagnosis of Urothelial Carcinoma. 2017 , 34, 1087-1096	23
107	Antitumor activity of sulfated hyaluronic acid fragments in pre-clinical models of bladder cancer. 2017 , 8, 24262-24274	13
106	Simple and effective label-free electrochemical immunoassay for carbohydrate antigen 19-9 based on polythionine-Au composites as enhanced sensing signals for detecting different clinical samples. 2017 , 12, 3049-3058	29
105	Identifying and analyzing different cancer subtypes using RNA-seq data of blood platelets. 2017 , 8, 87494-87511	11
104	Ten Years of Proteomics in Bladder Cancer: Progress and Future Directions. 2017 , 3, 1-18	16
103	Liquid biopsies for bladder cancer. 2017 , 6, 331-335	26
102	Requisite for Collection and Distribution of Tissue and Fluid Specimens for Molecular Diagnostics and Discovery in Bladder Cancer. 2018 , 103-116	
101	The global epidemiology of bladder cancer: a joinpoint regression analysis of its incidence and mortality trends and projection. 2018 , 8, 1129	114
100	Diagnostic potential of major and trace elements in the serum of bladder cancer patients. 2018 , 46, 150-155	13
99	Urine Cytology and Existing Urinary Biomarkers for Bladder Cancer. 2018 , 137-155	
98	Precision Molecular Pathology of Bladder Cancer. 2018 ,	

97	Clinical utility of a non-invasive urine test for risk assessing patients with no obvious benign cause of hematuria: a physician-patient real world data analysis. <i>BMC Urology</i> , 2018 , 18, 18	2.2	2
96	Molecular markers in disease detection and follow-up of patients with non-muscle invasive bladder cancer. 2018 , 18, 443-455		6
95	Clinical performance and utility of a NNMT-based urine test for bladder cancer. 2018 , 33, 94-101		17
94	A Novel Urine-Based Assay for Bladder Cancer Diagnosis: Multi-Institutional Validation Study. 2018 , 4, 388-394		10
93	Integrated analysis reveals down-regulation of SPARCL1 is correlated with cervical cancer development and progression. 2018 , 21, 355-365		17
92	Red patches during bladder cancer surveillance: to biopsy or not to biopsy?. 2018 , 7, 280-282		1
91	CD24 regulates cancer stem cell (CSC)-like traits and a panel of CSC-related molecules serves as a non-invasive urinary biomarker for the detection of bladder cancer. 2018 , 119, 961-970		18
90	Detection of Urothelial Bladder Carcinoma via Microfluidic Immunoassay and Single-Cell DNA Copy-Number Alteration Analysis of Captured Urinary-Exfoliated Tumor Cells. 2018 , 78, 4073-4085		24
89	Performance of Urinary Markers for Detection of Upper Tract Urothelial Carcinoma: Is Upper Tract Urine More Accurate than Urine from the Bladder?. 2018 , 2018, 5823870		15
88	Combined use of urinary Survivin detection and liquid-based cytology for the early diagnosis of bladder urothelial carcinoma. 2018 , 15, 7739-7743		4
87	MALBAC-based chromosomal imbalance analysis: a novel technique enabling effective non-invasive diagnosis and monitoring of bladder cancer. <i>BMC Cancer</i> , 2018 , 18, 659	4.8	1
86	Molecular Applications in Cytology. 2018 ,		1
85	Microchips for detection of exfoliated tumor cells in urine for identification of bladder cancer. 2018 , 1044, 93-101		4
84	Evaluation of a New Survivin ELISA and UBC Rapid for the Detection of Bladder Cancer in Urine. <i>International Journal of Molecular Sciences</i> , 2018 , 19,	6.3	16
83	Diagnostic accuracy of the UBC Rapid Test for bladder cancer: A meta-analysis. 2018 , 16, 3770-3778		5
82	Clinical and cytopathological factors affecting the cellularity of urinary cell blocks and the implication for diagnosis and follow-up of urinary bladder urothelial carcinoma. 2018 , 29, 537-544		6
81	KIF5A Promotes Bladder Cancer Proliferation and. 2019 , 2019, 4824902		6
80	Evaluation of the frequency of CD5 B cells as natural immunoglobulin M producers and circulating soluble CD5 in patients with bladder cancer. 2019 , 46, 6405-6411		2

79	Secular trends in incidence and mortality of bladder cancer in China, 1990-2017: A joinpoint and age-period-cohort analysis. 2019 , 61, 95-103		23
78	lncRNA TUC338 is a potential diagnostic biomarker for bladder cancer. 2019 , 120, 18014-18019		12
77	Targeted deep sequencing of urothelial bladder cancers and associated urinary DNA: a 23-gene panel with utility for non-invasive diagnosis and risk stratification. <i>BJU International</i> , 2019 , 124, 532-544	5.6	23
76	Diagnosis of urinary bladder urothelial carcinoma by immunocytology with p53, MCM5, MCM2 and Ki-67 antibodies using cell blocks derived from urine. 2019 , 30, 510-518		1
75	Epidermal Growth Factor Receptor (EGFR) Cell Expression During Adjuvant Treatment After Transurethral Resection for Non-Muscle-Invasive Bladder Cancer: A New Potential Tool to Identify Patients at Higher Risk of Disease Progression. 2019 , 17, e751-e758		10
74	Tropomyosins: Potential Biomarkers for Urothelial Bladder Cancer. <i>International Journal of Molecular Sciences</i> , 2019 , 20,	6.3	2
73	Urinary markers in the surveillance of non-muscle invasive bladder cancer. A literature review. 2019 , 43, 404-413		1
72	Identification of Cancer-Specific Methylation of Gene Combination for the Diagnosis of Bladder Cancer. 2019 , 10, 6761-6766		5
71	Urinary markers in the surveillance of non-muscle invasive bladder cancer. A literature review. 2019 , 43, 404-413		
70	Prospective Validation of an mRNA-based Urine Test for Surveillance of Patients with Bladder Cancer. 2019 , 75, 853-860		42
69	Strong Expression of Cancer-testis Antigens CTAG1B and MAGEA3 Is Correlated with Unfavourable Histopathological Features and MAGEA3 Is Associated with Worse Progression-Free Survival in Urothelial Bladder Cancer. <i>Urologia Internationalis</i> , 2019 , 102, 77-82	1.9	6
68	Can urinary biomarkers replace cystoscopy?. 2019 , 37, 1741-1749		25
67	Assessing the Clinical Benefit of UBC Rapid in the Surveillance and Initial Diagnosis of Bladder Cancer. 2020 , 18, 230-235		3
66	Extracellular vesicles in urological malignancies: an update. 2020 , 17, 11-27		41
65	Non-invasive Detection of Bladder Cancer by UBC Rapid Test, Ultrasonography and Cytology. 2020 , 40, 3967-3972		2
64	Diagnostic Performance of Novel Urine-Based mRNA Tests (Xpert and Urinary Metabolomics Markers Assay) for Bladder Cancer Detection in Patients with Hematuria. 2020 , 6, 319-328		3
63	Aristolochic acid and its effect on different cancers in uro-oncology. 2020 , 30, 689-695		2
62	Activating Telomerase Promoter Mutations and Their Application for the Detection of Bladder Cancer. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	5

61	Diagnostic Value of Telomerase Activity in Patients With Bladder Cancer: A Meta-Analysis of Diagnostic Test. 2020 , 10, 570127		
60	Urinary Biomarkers in Bladder Cancer: Where Do We Stand and Potential Role of Extracellular Vesicles. <i>Cancers</i> , 2020 , 12,	6.6	19
59	Use of the Nuclear Matrix Protein 22 BladderChek Test for the Detection of Primary and Recurrent Urothelial Carcinoma. 2020 , 2020, 3424039		0
58	Investigation of Atyp.C using UF-5000 flow cytometer in patients with a suspected diagnosis of urothelial carcinoma: a single-center study. 2020 , 15, 77		3
57	Urinary TERT promoter mutations are detectable up to 10 years prior to clinical diagnosis of bladder cancer: Evidence from the Golestan Cohort Study. 2020 , 53, 102643		23
56	Rapid noninvasive detection of bladder cancer using survivin antibody-conjugated gold nanoparticles (GNPs) based on localized surface plasmon resonance (LSPR). 2020 , 69, 1833-1840		7
55	Toward noninvasive follow-up of low-risk bladder cancer - Rationale and concept of the UroFollow trial. 2020 , 38, 886-895		11
54	Urinary Nucleic Acid in Tumor: Bioinformatics Approaches. 2021 , 2292, 95-104		1
53	MIBC Bladder Cancer Assessment and Diagnosis. 2021 , 81-89		
52	Prognostic value of albumin to globulin ratio in non-muscle-invasive bladder cancer. 2021 , 39, 3345-3352		3
51	Urinary Biomarkers: Current Status and Future Opportunities. 2021 , 163-192		
50	LncRNA MAFG-AS1 regulates miR-125b-5p/SphK1 axis to promote the proliferation, migration, and invasion of bladder cancer cells. 2021 , 34, 588-597		8
49	A Urine-Based Liquid Biopsy Method for Detection of Upper Tract Urinary Carcinoma. 2020 , 10, 597486		2
48	Low-Coverage Sequencing of Urine Sediment DNA for Detection of Copy Number Aberrations in Bladder Cancer. 2021 , 13, 1943-1953		1
47	Increased expression of urinary exosomal LncRNA TUG-1 in early bladder cancer. 2021 , 22, 101010		1
46	Urinary extracellular vesicles: a rising star in bladder cancer management. 2021 , 10, 1878-1889		2
45	Treating Bladder Cancer: Engineering of Current and Next Generation Antibody-, Fusion Protein-, mRNA-, Cell- and Viral-Based Therapeutics. 2021 , 11, 672262		4
44	Trends in urine biomarker discovery for urothelial bladder cancer: DNA, RNA, or protein?. 2021 , 10, 2787-2808		0

43	A 25-year perspective on evaluation and understanding of biomarkers in urologic cancers. 2021 , 39, 602-617	2
42	TiO ₂ /MXene-Assisted LDI-MS for Urine Metabolic Profiling in Urinary Disease. 2106743	3
41	Prediction of Metastatic Patterns in Bladder Cancer: Spatiotemporal Progression and Development of a Novel, Web-based Platform for Clinical Utility. 2021 , 32, 8-18	0
40	Developing non-invasive bladder cancer screening methodology through potentiometric multisensor urine analysis. 2021 , 234, 122696	5
39	Multiplex PCR and Next Generation Sequencing for the Non-Invasive Detection of Bladder Cancer. <i>PLoS ONE</i> , 2016 , 11, e0149756	3-7 5 ²
38	Review of non-invasive urinary biomarkers in bladder cancer.. 2020 , 9, 6554-6564	4
37	Massively parallel sequencing of urinary DNA-the dawn of non-invasive bladder cancer detection and surveillance?. 2019 , 8, S204-S207	2
36	LINC01638 lncRNA mediates the postoperative distant recurrence of bladder cancer by upregulating ROCK2. 2019 , 18, 5392-5398	6
35	What is new in non-muscle-invasive bladder cancer in 2016?. 2017 , 43, 9-13	25
34	[Rational follow-up of non-muscle invasive bladder cancer]. <i>Der Urologe</i> , 2021 , 60, 1409-1415	
33	Molecular Cytology Applications on Urine. 2018 , 117-126	
32	Urinmarker beim Blasenkarzinom. 2018 , 135-152	
31	Prognostic and Predictive Markers, and Stratifications Tables, for the Detection and Treatment of Renal Cell Carcinoma. 2019 , 511-528	
30	Improving the diagnosis of high grade and stage bladder cancer by detecting increased urinary calprotectin expression in tumor tissue and tumor-associated inflammatory response. <i>Investigative and Clinical Urology</i> , 2019 , 60, 343-350	1.9 1
29	Bladder Cancer Screening Systematic Review Results. 2020 , 73-98	
28	Bladder Cancer Screening Systematic Review Conclusion. 2020 , 99-101	
27	Bladder Cancer Diagnostic Pathways. 2020 , 65-67	
26	Screening for Occupational Cancer. 2020 , 603-611	

25	Antiplatelet Kullanımın Mesane Kanseri Tanısında Gerindeki Etkileri: Kolaylaştırıcı mı, Zorlaştırıcı mı? <i>Yeni Döloji Dergisi</i> , 2020 , 15, 3-4	0	0
24	A Google Trends Analysis of Bladder Cancer: Determining Awareness Campaign Success, and Patients' Needs in Clinical Management. <i>Asian Pacific Journal of Cancer Prevention</i> , 2021 , 22, 3115-3120	1.7	0
23	Genetic predisposition and prediction protocol for epithelial neoplasms in disease-free individuals: A systematic review. <i>Journal of Oral and Maxillofacial Pathology</i> , 2020 , 24, 293-307	1.2	1
22	Bioinformatics evaluation of the homologues of <i>Schistosoma mansoni</i> biomarker proteins of bladder cancer in other <i>Schistosoma</i> species.		
21	Urinary-Based Markers for Bladder Cancer Detection. <i>Société Internationale D'urologie Journal</i> , 2020 , 1, 49-61	0.1	
20	Urinary Exosomal miRNAs as biomarkers of bladder Cancer and experimental verification of mechanism of miR-93-5p in bladder Cancer. <i>BMC Cancer</i> , 2021 , 21, 1293	4.8	2
19	The relationship between urologic cancer outcomes and national Human Development Index: trend in recent years.. <i>BMC Urology</i> , 2022 , 22, 2	2.2	0
18	Nomograms including UBC-Rapid Test to detect primary bladder cancer based on a multicenter data set.. <i>BJU International</i> , 2021 ,	5.6	0
17	Liquid biopsy in bladder tumors. 2022 , 45-65		0
16	Perfil de Expresión de MicroRNAs (miRNAs) en Pacientes con Cáncer de Vejiga en un Hospital de Tercer Nivel. 2021 , 9, 15-21		
15	Diagnostic and prognostic factors in patients with prostate cancer: a systematic review.. <i>BMJ Open</i> , 2022 , 12, e058267	3	0
14	[Follow-up in superficial and metastatic bladder cancer].. <i>Der Urologe</i> , 2022 ,		
13	Urologic Cancer Molecular Biology.		
12	Rationale Nachsorge des nicht-muskelinvasiven Harnblasenkarzinoms. <i>Best Practice Onkologie</i> , 2022 , 17, 222-227	0	
11	Molecular Diagnostic and Prognostication Assays for the Subtyping of Urinary Bladder Cancer Are on the Way to Illuminating Our Vision. <i>International Journal of Molecular Sciences</i> , 2022 , 23, 5620	6.3	
10	Molecular Oncology of Bladder Cancer from Inception to Modern Perspective. <i>Cancers</i> , 2022 , 14, 2578	6.6	2
9	Exploring solid-phase proximity ligation assay for survivin detection in urine. <i>PLoS ONE</i> , 2022 , 17, e0270535	5.5	
8	Urine Cellular DNA Point Mutation and Methylation for Identifying Upper Tract Urinary Carcinoma. <i>Cancers</i> , 2022 , 14, 3537	6.6	0

- 7 EphA2 on urinary extracellular vesicles as a novel biomarker for bladder cancer diagnosis and its effect on the invasiveness of bladder cancer. 1
- 6 Urine-Based Markers for Detection of Urothelial Cancer and for the Management of Nonmuscle-Invasive Bladder Cancer. **2023**, 50, 53-67 0
- 5 Upregulation of MTHFD2 is associated with PD-L1 activation in bladder cancer via the PI3K/AKT pathway. **2022**, 51, 0
- 4 Predictive and Prognostic Role of the Neutrophil-to-Lymphocyte Ratio in Muscle Invasive Bladder Cancer Treated With Neoadjuvant Chemotherapy and Radical Cystectomy. **2023**, 0
- 3 CDCP1 (CUB domain containing protein 1) is a potential urine-based biomarker in the diagnosis of low-grade urothelial carcinoma. **2023**, 18, e0281873 0
- 2 Extracellular Vesicles as Potential Bladder Cancer Biomarkers: Take It or Leave It?. **2023**, 24, 6757 0
- 1 Evaluation of IGF2, KRT14, and KRT20 as Urinary Biomarkers in Patients with Bladder Cancer. **2023**, 11, 710-719 0